Scarica l'app Stockscreener
0.4641
0.72%
0.0033
Pre-mercato:
.44
-0.0241
-5.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener
Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat
Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga
The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU.com
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance
Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus
Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters
Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa
Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha
Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener
Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - Marketscreener.com
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com Australia
Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com
Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider.com
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR
Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50% - simplywall.st
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler Cuts Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target to $6.00 - Defense World
Equities Analysts Issue Forecasts for LXRX Q1 Earnings - Defense World
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages - Defense World
Lexicon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies - TipRanks
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges - TipRanks
LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
What Analysts Are Saying About Lexicon Pharmaceuticals Stock - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth - TipRanks
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com India
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Lexicon: Q4 Earnings Snapshot - KTEN
Lexicon Pharma beats Q4 estimates, shares rise on strong revenue - Investing.com India
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):